In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Effects of a cardiac rehabilitation program in patients with severe left ventricular dysfunction: can all benefit?

Session Poster session 1 Saturday 08:30 -17:30

Speaker Oscar Gonzalez Fernandez

Event : Heart Failure 2015

  • Topic : preventive cardiology
  • Sub-topic : Exercise Testing
  • Session type : Poster Session

Authors : N Montoro Lopez (Madrid,ES), O Gonzalez Fernandez (Madrid,ES), R Dalmau (Madrid,ES), C Alvarez Ortega (Madrid,ES), R Mori Junco (Madrid,ES), JL Lopez-Sendon (Madrid,ES)

Authors:
N Montoro Lopez1 , O Gonzalez Fernandez1 , R Dalmau1 , C Alvarez Ortega1 , R Mori Junco1 , JL Lopez-Sendon1 , 1University Hospital La Paz, Cardiology - Madrid - Spain ,

Citation:
European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 108

Introduction: Cardiac rehabilitation programs (CRP) after ST elevation myocardial infarction (STEMI) provide patients exercise, optimal medical treatment, education and counselling. Our objective was to analyze the functional impact of a CRP in this population and identify subgroup with more or less benefit.

Methods: We made an observational retrospective study including severe LSVD patients after STEMI admitted to a CRP in our institution between 2006 and 2014. Physical training, nutritional education, optimal medical treatment and medical counselling were supplied according to the CRP for 8 to 10 weeks. Left ventricular systolic function and functional capacity were tested before and after the CRP in accordance with the NYHA Functional Classification, besides a treadmill stress test (TST). Exercise capacity was reported in terms of estimated metabolic equivalents of task (METs).

Results: A total of 156 patients were included in our study, mean age 56.19 ± 12,22 years, male 90.4%. Prevalence of hypertension was 50.6%, diabetes 27.9%, dyslipidemia 55.8%, obesity 28.1%, current smoker 59%, chronic kidney disease (CKD) 5.1%, chronic obstructive pulmonary disease (COPD) 6.5% and cerebrovascular disease (CD) 1.9%. The NYHA class previous CRP was I 46.5%, II 43.7%, III 9.9%. Mean initial left ventricular ejection fraction (LVEF) was 29.93 ± 5.14%. As to TST results before the CRP, medium METs were 6.46 ± 2.98 and 5.9 ± 2,69 minutes was the mean exercise time (ET). After CRP, LVEF was 42.32 ± 10.52% (LVEF improvement compare to baseline, 12.41 ± 9.52%; p < 0.001). The NYHA class was  I 79.7%, II 19.5%, III 0.8%. Medium METs were 10.04 ± 2.98 (METs improvement 3.52 ± 2.06; p < 0.001) and mean ET was 8.65 ± 2.50 minutes (ET improvement 2.62 ± 2.90 minutes; p < 0.001). We did not find statistically significant differences in functional capacity or LVEF improvement according to sex, age, cardiovascular risk factors profile, CKD, COPD or CD.

Conclusions: Severe LVSD patients enrolled in a CRP after suffering an STEMI improve functional capacity and LVEF regardless their previous cardiovascular risk factors profile, CKD, COPD and CD.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are